The recent rejection in the US for its Fabry disease drug pegunigalsidase alfa partnered with Protalix BioTherapeutics, Inc. was clearly a setback for Chiesi Farmaceutici S.p.A. but the Italian company has a number of other partnerships that will help the company continue its strategy of becoming a major player in respiratory and rare diseases on a global scale.
Founded in 1935 in Parma by entrepreneurial chemist Giacomo Chiesi, the company has been best known for steadily building its expertise in Italy and the rest of Europe in the respiratory field
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?